IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies.
IgG subclasses differ in their effector functions in a variety of in vitro assays. To assess the effect of antibody subclass differences on in vivo protective efficacy against herpes simplex virus (HSV), a series of subclass switch mutants was made from an anti-HSV glycoprotein D monoclonal antibody. Purified antibody was examined for the ability to protect against HSV-2 challenge in mice. IgG2a was found to be more effective than IgG1. This correlated both with activity in antibody-dependent cell-mediated cytotoxicity and with efficiency of complement-mediated neutralization. These data suggest that optimization of passive immunization against HSV requires consideration of antibody subclass.
Ishizaka
S T
ST
Department of Viral Vaccine Research and Development, Lederle-Praxis Biologicals, Pearl River, New York 10965, USA.
Piacente
P
P
Silva
J
J
Mishkin
E M
EM
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D006561:Herpes Simplex / Q000517:prevention & control*; D018258:Herpesvirus 2, Human / Q000276:immunology; D007116:Immunization, Passive; D017578:Immunoglobulin Class Switching / Q000235:genetics; D007074:Immunoglobulin G / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D014759:Viral Envelope Proteins / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D007074:Immunoglobulin G; D014759:Viral Envelope Proteins; C040570:glycoprotein D-herpes simplex virus type 2